Description of the population
Among the 329 children included in the COBRAPed cohort with available ISAC data, 6 SRW and 28 SA receiving omalizumab at inclusion were excluded. Among the 295 remaining children, 47 were classified as (a) NSRW, 78 as (b) SRW, 108 as (c) NSA, and 62 as (d) SA (Fig 1). Their main characteristics are presented in Table 1. Children with SRW had significantly lower birth weight than those with NSRW (3100g [2600, 3430] vs 3380g [3102, 3550], p=0.004) and were more frequently exposed to second-hand smoke (22.7% vs 2.1%, p=0.004) and visible mold/dampness (28.2% vs 8.7%, p=0.019). Children with SA had a more frequent history of FA (26.7% vs 13.2%, p=0.05) and atopic dermatitis (AD) (46.8% vs 26.9%, p=0.014) than those with NSA. Atopy was found in 61.3% of preschool children and 82.2% of school-age children, without differences between NSRW and SRW or NSA and SA, respectively.